Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.

Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ.

J Immunol. 2004 Oct 15;173(8):5148-55.

2.

Use of CpG oligodeoxynucleotides as immunoprotective agents.

Klinman DM.

Expert Opin Biol Ther. 2004 Jun;4(6):937-46. Review.

PMID:
15174975
3.

CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques.

Verthelyi D, Wang VW, Lifson JD, Klinman DM.

AIDS. 2004 Apr 30;18(7):1003-8.

PMID:
15096802
4.
5.

Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions.

Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G.

J Leukoc Biol. 2003 Jun;73(6):781-92.

PMID:
12773511
6.

CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.

Verthelyi D, Gursel M, Kenney RT, Lifson JD, Liu S, Mican J, Klinman DM.

J Immunol. 2003 May 1;170(9):4717-23.

8.

The immunology of susceptibility and resistance to Leishmania major in mice.

Sacks D, Noben-Trauth N.

Nat Rev Immunol. 2002 Nov;2(11):845-58. Review.

PMID:
12415308
9.

CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells.

Gursel M, Verthelyi D, Klinman DM.

Eur J Immunol. 2002 Sep;32(9):2617-22.

10.

CpG motifs in bacterial DNA and their immune effects.

Krieg AM.

Annu Rev Immunol. 2002;20:709-60. Epub 2001 Oct 4. Review.

PMID:
11861616
11.

CpG oligodeoxynucleotides as vaccine adjuvants in primates.

Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM.

J Immunol. 2002 Feb 15;168(4):1659-63.

12.

CpG oligodeoxynucleotides enhance host defense during murine tuberculosis.

Juffermans NP, Leemans JC, Florquin S, Verbon A, Kolk AH, Speelman P, van Deventer SJ, van der Poll T.

Infect Immun. 2002 Jan;70(1):147-52.

13.

Leishmania (Leishmania) major-infected rhesus macaques (Macaca mulatta) develop varying levels of resistance against homologous re-infections.

Amaral VF, Teva A, Porrozzi R, Silva AJ, Pereira MS, Oliveira-Neto MP, Grimaldi G Jr.

Mem Inst Oswaldo Cruz. 2001 Aug;96(6):795-804.

14.

Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.

Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G.

Eur J Immunol. 2001 Jul;31(7):2154-63.

15.

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi G Jr.

Infect Immun. 2001 Jun;69(6):4103-8.

16.

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM.

J Immunol. 2001 Feb 15;166(4):2372-7.

17.
18.

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM.

J Immunol. 2000 Feb 1;164(3):1617-24.

19.
20.

Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.

Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K.

J Immunol. 1999 Oct 15;163(8):4481-8.

Supplemental Content

Support Center